NEW YORK, July 13, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at American Oriental Bioengineering Inc. ("AOBI" or the "Company") (OTC Markets: AOBI).

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that:  (1) certain of the Company's capsule products maintained chrome levels far exceeding humanly tolerable limits; (2) the Company's financial statements contained material inconsistencies; (3) the Company's internal controls over financial reporting were deficient; and (4), as a result of the foregoing, the Company's statements were materially false and misleading at all relevant times.

On March 16, 2012, the Company's independent registered public accounting firm, Ernst & Young Hua Ming ("E&Y"), informed AOBI's Audit Committee of inconsistencies in the Company's financial statements for fiscal year 2011.  Approximately one month later, on April 19, 2012, the Company disclosed "onsite short notice inspections" conducted by the Chinese State Food and Drug Administration at four of AOBI's five manufacturing subsidiaries after capsule products were discovered with chrome levels far exceeding humanly tolerable limits. Then, after being delisted by the New York Stock Exchange on May 25, 2012, the Company's common stock plummeted nearly 62% when it resumed trading over-the-counter on May 29, 2012.

On June 15, 2012, the Company disclosed that E&Y had withdrawn its audit reports for the Company's financial statements for the years ended 2009 and 2010, after E&Y concluded that it could no longer rely on management's representations in connection with its audits of the financial statements for those years.

Request more information now by clicking here:  www.faruqilaw.com/AOBI. There is no cost or obligation to you.

Take Action

If you purchased AOBI securities between November 9, 2009 and June 15, 2012 and would like to discuss your legal rights, visit www.faruqilaw.com/AOBI.  You can also contact us by calling Juan Monteverde, Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to jmonteverde@faruqilaw.com, rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding AOBI's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential matter.



FARUQI & FARUQI, LLP

369 Lexington Avenue, 10th Floor

New York, NY 10017

Attn:  Juan Monteverde, Esq.

jmonteverde@faruqilaw.com

Richard Gonnello, Esq.

rgonnello@faruqilaw.com

Francis McConville, Esq.

fmcconville@faruqilaw.com

Telephone: (877) 247-4292 or (212) 983-9330

 

SOURCE Faruqi & Faruqi, LLP

Copyright 2012 PR Newswire

American Oriental Bioeng... (CE) (USOTC:AOBI)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024 American Oriental Bioeng... (CE) 차트를 더 보려면 여기를 클릭.
American Oriental Bioeng... (CE) (USOTC:AOBI)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024 American Oriental Bioeng... (CE) 차트를 더 보려면 여기를 클릭.